Emmanuel Katongole’s QCIL gets $36 million for new pharma plant in Uganda
Uganda’s QCIL gets $36 million Stanbic loan for second pharma plant, aims to scale drug output and locally manufacture TB treatments for regional markets.
Emmanuel Katongole
QCIL posts over 500-percent profit surge to $6 million
Pharmaceutical leader reports robust growth in revenue and margins.
Ugandan pharma tycoon Emmanuel Katongole’s CiplaQCIL stake plunges to less than $2 million
East Africa’s healthcare industry, Katongole, holds a significant 2.79-percent stake in CiplaQCIL.
Ugandan pharma tycoon Emmanuel Katongole’s stake in CiplaQCIL now worth $1.9 million
CiplaQCIL’s total assets have surpassed $64 million.
Ugandan tycoon Emmanuel Katongole’s CiplaQCIL set to sell majority stake to Africa Capitalworks
Katongole owns a 2.79-percent equity stake in the Uganda-based pharmaceutical company.
Ugandan tycoon Emmanuel Katongole’s CiplaQCIL to pay shareholders first dividend in four years
Katongole owns 2.79 percent of the company, or 101,933,042 ordinary shares.
Ugandan pharma tycoon Emmanuel Katongole loses over $1 million in one year
Katongole owns 2.79 percent of the company, which translates to 101,933,042 ordinary shares.
Ugandan tycoon Emmanuel Katongole’s stake in CiplaQCIL is worth $2.87 million
CiplaQCIL is a pharmaceutical company based in Luzira, a suburb of Kampala, the capital city of Uganda.
Stake of Ugandan pharma tycoon Emmanuel Katongole in CiplaQCIL rises by $200,000 since April 13
The growth in his stake follows a rise in the shares of CiplaQCIL on the Uganda Stock Exchange.